Orthocell (OCC) Investor presentation summary

Commercialisation and market strategy

• Remplir, a collagen nerve repair device, is being commercialized with growing international revenue and a US market launch underway.

• US market access activities are progressing as planned, with sales building and a clear path to breakeven at 5,000–6,000 procedures annually, less than 1% of the addressable market.

• Strategic focus includes winning in the Americas, accelerating growth in ANZ and Asia, and scaling a global collagen medical device platform.

• FY26 priorities are US market access, Asia expansion, UK/EU launch planning, and recruiting specialist talent.

Product and clinical innovation

• Remplir mimics the natural epineurium, creating an optimal healing environment for nerve regeneration and simplifying the surgical process.

• Current US nerve repair market is $1.6B, with devices used in only ~10% of 700,000+ annual procedures; Remplir aims to address limitations of existing devices.

• New application in prostate cancer surgery to preserve nerve function could significantly expand the total addressable market; initial patient data expected 1H CY26.

Financial performance and growth

• Revenue has shown constant growth over the last three halves, driven by device sales, with a compound semi-annual growth rate of +21%.

• US Remplir adoption has surged, with hospitals growing to 52, surgeons to 48, and unit sales above 110–120 per quarter within 9 months of launch.

• AU/NZ Remplir sales have nearly doubled year-over-year, with 314 surgeons and 224 hospitals using the product.

• Cash reserves of $49.4M as of December 2025 support ongoing US rollout and growth initiatives.